DescriptionThis preprint proposes a new biological classification for N,N-dimethyltryptamine (DMT): crisis-linked endogenous consciousness modulators (cECMs). Using six mechanistically grounded, falsifiable criteria—endogenous neural biosynthesis, deep evolutionary conservation, ultra-rapid pharmacokinetics, multi-receptor promiscuity, crisis-linked release, and induction of information-rich...
Abstract This study explores the first-time use of psychedelic macrodoses among Latin American adults, addressing a gap in the literature regarding naturalistic use outside clinical settings. A total of 4,810 participants from six Latin American countries completed an online survey assessing sociodemographic characteristics, substances used, consumption contexts, motivations, and subjective...
Abstract Disorders of consciousness (DoC), including unresponsive wakefulness syndrome (UWS) and minimally conscious state (MCS), have limited treatment options and are characterized by low complexity of brain activity. Recent research suggests that psychedelic drugs, which enhance the complexity of brain activity, could offer promising therapies. Here, individualized whole‐brain computational...
November 17, 2025Tony R. Montgomery, Demond M. Grant
Recent research into classical psychedelics, such as psilocybin, LSD, and DMT, has highlighted their therapeutic potential for mental health disorders. However, emerging evidence suggests their utility may extend beyond treatment into the realm of preventive medicine. This manuscript proposes a novel framework positioning psychedelics as agents of cellular and psychological rejuvenation....
Serotonergic psychedelics, particularly psilocybin, lysergic acid diethylamide (LSD), and dimethyltryptamine (DMT), are increasingly recognised as powerful tools to advance the understanding of consciousness and its relation to brain activity. Psychedelic research has informed neuroscientific theories that attempt to map neural observations of network connectivity and signal diversity to...
The meta-analysis of the 11-dimensional Altered States of Consciousness (11D-ASC) included three studies that contained duplicated data from other papers: Duerler et al. (2021), Lewis et al. (2017), and Preller et al. (2017). When these studies are removed from the analysis, the results are generally similar to the previously reported findings. Out of 33 comparisons (3 doses x 11 dimensions)...
Serotonergic psychedelics and 3,4-methylendioxtmethamphetamine (MDMA) are promising treatments for mental disorders with a continuously evolving evidence base. We searched Pubmed/Scopus/clinical trial registries up to 08july2025 for double-blind randomized controlled trials (RCTs) testing MDMA or serotonergic psychedelics in patients with mental disorders. Primary outcomes were change in...
From left to right, results refer to LSD, ketamine, and psilocybin drugs. Panel rows represent (a) the raw values of PID atoms, (b) the NMI-normalised PID atoms, and (c) the NuMIT-normalised PID atoms. The dashed black lines are drawn at zero. (P-values calculated with a one-sample t-test against the zero-mean null hypothesis. *: ppp<0.001).
BackgroundTaking very small doses of psychedelics (LSD, truffles) over an extended period became prevalent in Western societies for its alleged cognitive benefit, including enhanced creativity. However, in the absence of robust, double-blind-controlled quantitative studies, such claims remain anecdotal.MethodsHere we present results from 3 double-blind placebo-controlled longitudinal trials...
Background and AimsThe ongoing opioid epidemic remains a major public health crisis in the United States, with over 100,000 opioid-related deaths annually. Mental health disorders are strongly associated with opioid use disorder (OUD), compounding risks of misuse and overdose. Emerging evidence indicates that psychedelics may be associated with reduced risk of OUD. This study aimed to estimate...